# The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

> **NCT05295732** · PHASE3 · COMPLETED · sponsor: **Timber Pharmaceuticals Inc.** · enrollment: 153 (actual)

## Conditions studied

- Ichthyosis

## Interventions

- **DRUG:** TMB-001
- **DRUG:** Matching Vehicle

## Key facts

- **NCT ID:** NCT05295732
- **Lead sponsor:** Timber Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-06-17
- **Final completion:** 2024-09-23
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295732, "The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05295732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*